CoChat

Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss

Open access

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Purpose: A surge in the use of semaglutide injection (Ozempic ® ) approved to treat type 2 diabetes (T2D) has led to a global supply shortage. We investigated contemporary user rates and clinical characteristics of semaglutide (Ozempic ® ) users in Denmark, and the extent of “off-label” prescribing for weight loss. Patients and Methods: Nationwide population-based cross-sectional study based on linked health registries January 2018 through December 2023. All adults who received a first prescription of semaglutide once weekly (Ozempic ® ) were included. We examined quarterly rates of new users and total user prevalences, using other glucagon-like peptide-1 receptor agonists and weight loss medications as comparison. We also investigated user characteristics including T2D, glucose control, comedications, and cardiorenal disease. Results: The new user rate of semaglutide (Ozempic ® ) remained stable at approximately 4 per 1000 adult person-years between 2019 and 2021 and then accelerated, peaking at 10 per 1000 in the first quarter of 2023 after which it declined sharply. User prevalence increased to 91,626 users in Denmark in 2023. The proportion of semaglutide (Ozempic ® ) new users who had a record of T2D declined from 99% in 2018 to only 67% in 2022, increasing again to 87% in 2023. Among people with T2D who initiated semaglutide (Ozempic ® ) in 2023, 52% received antidiabetic polytherapy before initiation, 39% monotherapy, and 8% no antidiabetic therapy. Most T2D initiators had suboptimal glucose control, with 83% having an HbA1c ≥ 48 mmol/mol and 68% ≥ 53 mmol/mol despite use of antidiabetic medication, and 29% had established atherosclerotic cardiovascular disease or kidney disease. Conclusion: The use of semaglutide (Ozempic ® ) in Denmark has increased dramatically. Although not approved for weight loss without T2D, one-third of new users in 2022 did not have T2D. Conversely, most initiators with T2D had a clear medical indication for treatment intensification, and “off-label” use can only explain a minor part of the supply shortage. Keywords: drug utilization, epidemiology, anti-obesity drugs, glucose-lowering drugs, obesity, type 2 diabetes

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/clep.s456170

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Quarterly incidence rate of new users (A) and quarterly total user prevalence (B) of semaglutide injection (Ozempic®) in Denmark, 2018–2023. Use of other GLP-1RAs and older weight loss medications shown as comparison.
Figure 1 Quarterly incidence rate of new users (A) and quarterly total user prevalence (B) of semaglutide injection (Ozempic®) in Denmark, 2018–2023. Use of other GLP-1RAs and older weight loss medications shown as comparison.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. Iannone, 2023, Diabetes Obes Metab, 25, 2535, 10.1111/dom · doi:10.1111/dom

Cited by

Metadata

Authors
Mailhac, A., Pedersen, L., Pottegård, A., Søndergaard, J., Mogensen, T., Sørensen, H., & Thomsen, R.
Affiliations
  • Aarhus University (DK)
  • University of Southern Denmark (DK)
  • Danish Medicines Agency (DK)
Corresponding author
Thomsen, Reimar
Venue
Clinical Epidemiology
Published
2024-04
Volume
Volume 16
Pages
307-318
ISSN
1179-1349 (ISSN-L)
OpenAlex
W4395085097
Cited by
60
References
24
Citations by year
2026: 25 · 2025: 29 · 2024: 6
FWCI
19.66
Type
journal article
Language
en
Open access
Locations
  • Clinical Epidemiology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (acceptedVersion, other-oa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Aarhus Universitet
  • Aarhus Universitetshospital
  • Novo Nordisk
  • Sundhedsstyrelsen
  • Diabetesforeningen
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
semaglutide, Ozempic, off-label drug use, weight loss, type 2 diabetes, GLP-1 receptor agonists, drug use trends, drug shortages, glycemic control, HbA1c, atherosclerotic cardiovascular disease, kidney disease, Denmark, prescribing patterns

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.